Revvity’s ACD/Labs Deal Strengthens Pharmaceutical Molecular Design Software Capabilities

Introduction

Revvity’s acquisition of Advanced Chemistry Development, Inc. (ACD/Labs) is strengthening its position in scientific software for pharmaceutical research, particularly in molecular design, analytical characterization, and chemical informatics.

The acquisition was completed in January 2026, bringing ACD/Labs into Revvity Signals Software. ACD/Labs provides software solutions used across pharmaceutical and materials science research, helping scientists manage complex chemical information and make better decisions throughout the research and development process.

Expanding Pharmaceutical Molecular Design Capabilities

One of the most important aspects of the deal is ACD/Labs’ expertise in molecular design and chemical intelligence.

Its Percepta platform provides AI-driven molecular property and ADMET prediction capabilities, while other ACD/Labs solutions support analytical characterization, chemical structure analysis, experimentation, and pharmaceutical development. These technologies can help researchers evaluate molecules earlier in the development process and make more informed decisions about potential candidates.

For pharmaceutical companies, better molecular prediction and characterization can help reduce unnecessary experimental work and improve the efficiency of drug discovery and development workflows.

Connecting Molecular Design With Analytical Science

The acquisition is not limited to adding molecular-design software to Revvity’s portfolio. A key objective is to connect molecular information, analytical data, and scientific workflows within Revvity Signals.

ACD/Labs’ Spectrus platform provides advanced spectral analysis, while Percepta focuses on molecular property prediction. Other solutions, including Katalyst D2D and Luminata, support experimentation, pharmaceutical chemistry, manufacturing, and controls decision-making.

Combining these capabilities with Revvity Signals could allow pharmaceutical researchers to move more easily between molecular design, experimentation, analytical characterization, and development.

Supporting Faster Drug Development

Drug development generates large amounts of complex data at every stage. Researchers need to understand molecular structures, evaluate properties, analyze experimental results, monitor purity, and determine whether promising candidates can ultimately be developed into reliable products.

ACD/Labs’ software addresses several of these requirements. Its technologies are designed to help scientists identify and characterize molecules, monitor purity and quality, and support robust production processes.

By integrating these capabilities into a broader informatics environment, Revvity aims to help scientists interpret and act on scientific information more efficiently.

ACD/Labs Adds More Than 200 Employees

The transaction also brings ACD/Labs’ specialized workforce into Revvity. ACD/Labs has more than 200 employees, including scientists, informatics specialists, and experts in chemical disciplines.

The company has supported scientific R&D organizations since 1994 and serves customers across pharmaceutical, chemical, food and beverage, environmental, agrochemical, flavors and fragrances, government, and educational markets.

This expertise is strategically valuable because pharmaceutical informatics requires more than software development. It requires a detailed understanding of chemistry, analytical science, laboratory workflows, and the needs of scientists.

Financial Details of the Deal

Revvity completed the ACD/Labs acquisition for $72 million in cash at closing, with up to $8 million in additional contingent consideration based on certain revenue metrics through 2028.

Revvity reported the acquired operations within its Life Sciences segment. The company also recorded approximately $32 million in goodwill, while identifiable intangible assets included developed technology, customer relationships, trade names and trademarks, and backlog.

The relatively targeted acquisition gives Revvity access to an established scientific software portfolio and specialized talent while expanding its broader informatics strategy.

Revvity Signals Gains a Broader Role

The ACD/Labs acquisition supports Revvity’s strategy of making Signals a more comprehensive scientific software environment.

Revvity originally described the transaction as a way to expand the breadth and depth of Signals and bridge the gap between analytical data and actionable scientific insights. The combined capabilities are intended to support workflows from discovery and development through scale-up and manufacturing.

This approach is increasingly relevant as pharmaceutical companies seek to reduce data silos and create more connected digital R&D environments.

Integration Is Already Showing Progress

The integration of ACD/Labs into Revvity Signals is already progressing. In August 2026, Revvity management said the integration was moving faster than anticipated, with early momentum in synergy realization and product interoperability across the combined offerings. ACD/Labs contributed approximately 75 basis points to Revvity’s second-quarter 2026 revenue growth.

This suggests the acquisition is beginning to contribute not only strategically but also commercially.

Broader Shift Toward Digital Pharmaceutical R&D

The deal comes as pharmaceutical companies increasingly adopt digital tools, AI, and advanced informatics to improve research productivity.

Molecular design is becoming particularly important as drug developers seek to evaluate larger numbers of potential compounds and understand their properties earlier. Software that combines molecular intelligence with experimental and analytical information can help researchers make decisions without treating each stage of development as a separate process.

Revvity’s integration of ACD/Labs therefore fits into a wider industry movement toward connected, data-driven pharmaceutical R&D.

Outlook

Revvity’s continued integration of ACD/Labs could strengthen its competitive position in pharmaceutical research informatics. The combination of Revvity Signals with ACD/Labs’ molecular design, analytical characterization, and chemical intelligence capabilities provides an opportunity to create a more comprehensive software ecosystem for scientific organizations.

The company is also expanding its broader Signals portfolio. In 2026, Revvity launched additional software initiatives, including Signals AI and Signals BioDesign, demonstrating its continued focus on AI-enabled and cloud-based scientific workflows.

Conclusion

Revvity’s acquisition of ACD/Labs represents a strategic move to strengthen its capabilities in pharmaceutical molecular design, analytical science, and research informatics.

ACD/Labs brings specialized molecular prediction, spectral analysis, chemical informatics, and pharmaceutical development software, while Revvity provides the broader Signals platform and global life sciences infrastructure. Together, these capabilities can help pharmaceutical researchers connect molecular design with analytical data, experimentation, development, and manufacturing.

As drug discovery becomes increasingly data-intensive and AI-driven, the ability to integrate molecular intelligence with scientific workflows could become an important competitive advantage. The ACD/Labs acquisition positions Revvity to play a larger role in this evolving pharmaceutical software market.